Cargando…

Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer

Circulating tumor DNA (ctDNA) is one conventional type of liquid biopsy that can be collected to dynamically monitor disease status. However, its potential clinical value and concordance with ascites samples or tumor biopsy needs to be evaluated further for patients with ovarian cancer. Therefore, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jie, Xiaoxiang, Du, Ming, Zhang, Meng, Jin, Xiayu, Cai, Qingqing, Xu, Congjian, Zhang, Xiaoyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366257/ https://www.ncbi.nlm.nih.gov/pubmed/35978934 http://dx.doi.org/10.3892/etm.2022.11479

Ejemplares similares

Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients
por: Kfoury, Maria, et al.
Publicado: (2023)

Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer
por: Han, Mi-Ryung, et al.
Publicado: (2020)

Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma
por: Ge, Zhouhong, et al.
Publicado: (2021)

Next-Generation Sequencing Panel Analysis of Clinically Relevant Mutations in Circulating Cell-Free DNA from Patients with Gestational Trophoblastic Neoplasia: A Pilot Study
por: Luo, Lingxiao, et al.
Publicado: (2020)

Immune Tumor Microenvironment in Ovarian Cancer Ascites
por: Almeida-Nunes, Diana Luísa, et al.
Publicado: (2022)

Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast Cancer
por: Huang, Chi-Cheng, et al.
Publicado: (2023)

Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer
por: Jie, Xiao-Xiang, et al.
Publicado: (2022)

Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer
por: Jin, Xiayu, et al.
Publicado: (2022)

Aquaporin 5 expression is altered in ovarian tumors and ascites-derived ovarian tumor cells in the chicken model of ovarian tumor
por: Tiwari, Anupama, et al.
Publicado: (2014)

Tumor cell-fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer
por: Han, Qing, et al.
Publicado: (2019)

Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer
por: Chen, Qian, et al.
Publicado: (2019)

Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients
por: Liu, Yong, et al.
Publicado: (2017)

PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study
por: Tzanikou, Eleni, et al.
Publicado: (2019)

Fragment Enrichment of Circulating Tumor DNA With Low-Frequency Mutations
por: Liu, Xiaojun, et al.
Publicado: (2020)

An Ovarian Steroid Cell Tumor Causing Virilization and Massive Ascites
por: Kim, Young Tae, et al.
Publicado: (2007)

The Proangiogenic Capabilities of Malignant Ascites Generated by Aggressive Ovarian Tumors
por: Mikuła-Pietrasik, Justyna, et al.
Publicado: (2017)

Etiology of Ascites and Pleural Effusion Associated with Ovarian Tumors: Literature Review and Case Reports of Three Ovarian Tumors Presenting with Massive Ascites, but without Peritoneal Dissemination
por: Miyoshi, Ai, et al.
Publicado: (2015)

Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer
por: Cheng, Xianliang, et al.
Publicado: (2017)

Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing
por: Guo, Qiaomei, et al.
Publicado: (2018)

Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors
por: Latifi, Ardian, et al.
Publicado: (2012)

Identification of Tissue-Resident Natural Killer and T Lymphocytes with Anti-Tumor Properties in Ascites of Ovarian Cancer Patients
por: Bernson, Elin, et al.
Publicado: (2023)

Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells
por: Yu, Yi, et al.
Publicado: (2014)

Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer
por: Ratajska, Magdalena, et al.
Publicado: (2017)

RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA
por: Giannopoulou, Lydia, et al.
Publicado: (2017)

An Improved Detection of Circulating Tumor DNA in Extracellular Vesicles-Depleted Plasma
por: Sun, Li, et al.
Publicado: (2021)

Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells
por: Yu, Yi, et al.
Publicado: (2014)

Ascites and Serial Plasma Circulating Tumor DNA for Predicting the Effectiveness of Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis
por: Pu, Xiaolin, et al.
Publicado: (2022)

Epidermal growth factor induces platelet-activating factor production through receptors transactivation and cytosolic phospholipase A(2) in ovarian cancer cells
por: Yu, Yi, et al.
Publicado: (2014)

Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact
por: Noguchi, Tomoko, et al.
Publicado: (2020)

Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer
por: Chao, Angel, et al.
Publicado: (2023)

Characterization of Ascites-Derived Ovarian Tumor Cells from Spontaneously Occurring Ovarian Tumors of the Chicken: Evidence for E-Cadherin Upregulation
por: Tiwari, Anupama, et al.
Publicado: (2013)

Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?
por: Yu, Ming, et al.
Publicado: (2021)

Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer
por: Kim, Soochi, et al.
Publicado: (2016)

Concordance between whole exome sequencing of circulating tumor DNA and tumor tissue
por: Leenanitikul, Julanee, et al.
Publicado: (2023)

Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer
por: Yang, Fang, et al.
Publicado: (2021)

DNA Repair Protein HELQ and XAB2 as Chemoresponse and Prognosis Biomarkers in Ascites Tumor Cells of High-Grade Serous Ovarian Cancer
por: Zhu, Fang, et al.
Publicado: (2022)

Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations
por: Ogasawara, Aiko, et al.
Publicado: (2020)

Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer
por: Paracchini, Lara, et al.
Publicado: (2022)

Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy
por: Zhang, Mengyu, et al.
Publicado: (2018)

Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer
por: Zheng, Xiaocui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_opc8urrd88ufeea4cgkutfqpv3